Extended Data Table 4 Summary of serious adverse events

From: Clinical improvement in psoriasis with specific targeting of interleukin-23

  1. *Subject 5 had a serious adverse event (SAE) of increased cardiac enzymes (44 weeks after treatment) and myositis (58 weeks after treatment); treatment of the condition with prednisone likely contributed to the cytomegalovirus infection (59 weeks after treatment). The primary investigator did not consider these serious adverse events to be related to study medication. **In subject 6, the convulsion event was confounded by the patient’s recent history of alcohol abuse, acute alcohol and benzodiazepine withdrawal as well as lack of sleep preceding the event. The investigator considered the event to possibly be related to the study drug owing to its long half-life; the event occurred 17 days after the second dose of 10 mg kg−1 tildrakizumab.
Back to article page